FDA Panel Will Have To Resolve Bleeding Risk With Merck’s Vorapaxar
This article was originally published in The Pink Sheet Daily
Executive Summary
Novel antiplatelet product has suffered from excess bleeding rates in clinical trials and is searching for an appropriate patient population, after initial hopes of being a blockbuster.
You may also be interested in...
“Use With Caution” Isn’t Specific Enough For Labeling, FDA Tells Merck At Vorapaxar Panel
Advisory committee struggles to give a labeling recommendation for lightweight patients, who saw lower efficacy using the platelet inhibitor.
FDA Reviewers Say Vorapaxar Approvable, But Question Study Changes
As the platelet inhibitor heads to an advisory committee, agency reviewers raise issues about safety-based changes to its Phase III trials.
Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar
Outcomes study of about 25,000 patients shows novel antiplatelet drug reduces events but also increases major bleeding, including intracranial hemorrhage.